8 research outputs found
Design, synthesis, and pharmacological evaluation of novel oxadiazole and oxadiazoline analogs as anti-inflammatory agents
Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months
S1 to S6 Tables on the supporting information of study result.
S1 to S6 Tables on the supporting information of study result.</p
Distribution of SARS-CoV-2 seropositive of participants by site, round and age group (<18 years and ≥18 years).
Distribution of SARS-CoV-2 seropositive of participants by site, round and age group (<18 years and ≥18 years).</p
Distribution of SARS-CoV-2 seropositive participants by site and round.
Distribution of SARS-CoV-2 seropositive participants by site and round.</p
Distribution of SARS-CoV-2 seropositive of participants by round, vaccination status and site.
Distribution of SARS-CoV-2 seropositive of participants by round, vaccination status and site.</p
Distribution of participants by change in SARS-CoV-2 seropositivity status by round and area.
Distribution of participants by change in SARS-CoV-2 seropositivity status by round and area.</p
Distribution of SARS-CoV-2 seropositive participants by site, round, and sex.
Distribution of SARS-CoV-2 seropositive participants by site, round, and sex.</p